Breaking News Bar

Business News and Information

Jazz acquires rights to experimental PTSD drug from SpringWorks in deal valued at up to $410M

The deal includes an upfront payment of $35 million.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear